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The main strategy to prevent transfusion-associated Chagas’ disease is the identification of T.
cruzi-infected blood donors by serological screening tests, however there is no perfect serological
gold standard. We evaluated an enzyme immunoassay (EIA), an indirect hemaglutination (IHA),
and an indirect immunofluorescence (IIF) test for detecting T. cruzi antibodies in Brazilian blood
donors. The results were submitted to latent class analysis, and a radioimmunopreciptation (RIPA)
test was performed on repeatedly positive samples. Among 1951 donors, 11 (0.56%) were positive
by EIA, 6 (0.31%) by IHA and 16 (0.82%) by IIF. Six samples were positive with all tests, while 4
reacted with EIA and IIF. The RIPA was positive in 6 (75.0%), 7 (66.6%), and 4 (54.0%) samples
reacting by the EIA, IHA and IIF tests, respectively. The latent class model detected a high sensitivity
rate (100%) for the EIA and IIF, and a specificity rate of  99.95% and 99.69% for the EIA and IIF
tests, respectively. The probability of being case according to the model was 99.92% when both
EIA and IIF were positive, and 100% for the association of EIA, IIF, and IHA.
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The current methods for detecting chronic T. cruzi
infection are mainly based on identification of serum
antibodies to the parasite [1] however, the serological
diagnosis of infection is complex, falsely yielding both
positive and negative results [2-4]. One additional
problem that these assays must overcome is a potential
cross-reactivity with other related protozoan diseases,
particularly leishmaniasis [5]. For situations such as this,
where there is no perfect serological gold standard,
latent class analysis may be used to evaluate the
sensitivity and specificity of diagnostic tests [6]. This
method assumes that the true disease state is not directly
unobservable, but that the available methods of
observation approximate the true state in some way
[7,8]. We evaluated the performance of three
commercially available serologic tests for detecting
antibodies to T. cruzi among Brazilian blood donors.
The serological results detected by enzyme
immunoassay (EIA), indirect hemaglutination (IHA),
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and indirect immunofluorescence (IIF) methods were
submitted to latent class model analysis. In addition,
samples that gave repeatedly positive results by the
serological screening tests were analyzed with a
supplementary radioimmunopreciptation (RIPA)
technique [9,10].
Materials and Methods
Study population. The blood donor population
consisted of 1951 subjects who donated blood in São
Paulo City, a non-endemic area for Chagas’ disease in
Brazil. Since most of the donors originated from different
regions of Brazil, they were selected by a pre-donation
questionnaire that included questions regarding their
epidemiological risk of T. cruzi infection. Donors were
asked: (1) Do you know the insect that transmits
Chagas’ disease?; and/or (2) Have you ever lived in a
house with contaminated with this insect?
Laboratory tests. All sera were screened by three
commercially available tests, including: (1) second
generation EIA that used purified antigens derived from
epimastigote  and amastigote forms of Y and CL T.
cruzi strains (Abbott Laboratories, Abbott Park, IL)
[11]; (2) IHA that employed antigens from epimastigote
and amastigote forms of Y and CL T. cruzi strains at a
1-in-40 serum dilution (Biolab Diagnóstica, RJ, Brazil)
[12]; and (3) IIF that was done using antigens from
epimastigote forms of T. cruzi in a 1-to-20 serum
dilution (Biolab Diagnóstica, RJ, Brazil) [13]. Results
were considered positive or negative by the EIA
according to the cut-off value obtained by the mean
value of the optical density (OD) from the negative
controls plus 0.360, and then multiplied by the mean
value of OD from the positive controls. An EIA result
was considered negative at an OD identical to or higher
than 0.020 but lower than the cut-off value, while an
EIA result was considered initially reactive at an OD
higher or identical to the cut-off value. The initially
reactive samples were reevaluated in duplicate and if
one of them was reactive, the sample was considered
repeatedly reactive. If both duplicate tests were
negative, the sample was considered negative for the
presence of T. cruzi-antibodies.
For the IHA, results were considered negative when
a pellet of red cells was formed at the bottom of the
microplate well; results were considered positive when
a uniform veil of red cells was formed covering all of
the microplate well. A cloudy layer of red cells at the
bottom of the microplate well was considered weakly
positive or indeterminate. All initially positive or
indeterminate samples were reevaluated in duplicate
and if one of the duplicate tests was positive the sample
was considered repeatedly positive.
A continuous emission of green fluorescence on the
membrane of the T. cruzi in the IIF test was scored as
a positive result while tests with an absent or a
discontinuous (non-specific) pattern of green
fluorescence emission on this membrane were
considered negative. An IIF result was considered
positive at a dilution titer of ≥ 20, and IHA at a dilution
titer of ≥ 40.
To properly evaluate the sensitivity of the serological
tests we examined 35 samples from persons with
chronic T. cruzi infection confirmed by a xenodiagnosis
test. The supplementary RIPA test was performed using
a lysate prepared from extracted membrane proteins
of T. cruzi. 125I labeled proteins were incubated with
each sample and then immunoprecipitated using Protein
A Sepharose. The eluted proteins were
electrophoresed using acrylamide gels and imaged using
autoradiography film. Samples with antibodies to T.
cruzi showed reactivity to p32 and p34, and a band at
p90 gave additional supporting data [9,10].
Statistical analysis. The latent class model allows for
false-positive and false-negative errors to occur at
certain rates in the test data; the test sensitivity is 1 –
FNR (false negative rate) and the test specificity is 1 –
FPR (false positive rate). For example, a positive test
result is interpreted in the model as having come from
either a true case of disease (thus, a correct result) or
from a non-case (thus, an incorrect, false positive
error). The mixing of these two possibilities occurs at
unknown proportions, defined by the true disease
prevalence [6].
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Using data from a set of individuals with several
test results each, the model can estimate the error rates
(or, equivalency, sensitivity and specificity) for each test
and the disease prevalence. Observational errors are
assumed to be conditionally independent (i.e. given the
true disease state of an individual) between tests. A
minimum of three tests is required to fit the model
without making further assumptions about the
parameter values. Parameter estimation  is achieved
by standard maximum likelihood methods, which also
yield standard errors for the parameters [6-8].
Results
Among 1,951 blood donors, 17 (0.87%) showed
positive results by at least one technique. Eleven
(0.56%) samples were positive by EIA, 6 (0.31%) by
IHA  and 16 (0.82%) by IIF. Only 6 (0.31%)
individuals gave positive results by all three tests, and
4 (0.20%) samples reacted to only two tests (EIA and
IIF). Four (0.20%) individuals reacted exclusively to
one test [3 (0.15%) by IIF, and 1 (0.05%) by EIA]
(Table 1).
The results of the RIPA investigation are summarized
in Table 2. The RIPA test was found to be positive in 6
(85.7%) of 7, 4 (66.7%) of 6 and 7 (58.3%) of 12
tested samples that reacted exclusively with the EIA,
IHA and IIF tests, respectively. In addition, we found
that the RIPA test was positive in 4 (80%) of 5 samples
that reacted simultaneously with the EIA, IHA and IIF
tests, and in 2 (100%) samples that were positive by
EIA and IIF.
Table 3 shows the parameters estimated from the
data incorporating EIA, IHA and IIF. All three tests
appear to have excellent specificity values; the sensitivity
was excellent for EIA and IIF, but IHA had a false
negative rate of approximately 40 percent. Accordingly,
the predictive values associated with almost all
combinations of tests results were very close to 0 or 1
(Table 4).
The serological investigation of 35 known positive
samples confirmed by a xenodiagnosis test showed a
sensitivity rate of 100, 100 and 88.2% for EIA, IIF,
and IHA, respectively. The RIPA test was found to be
positive in 29/31 (93%), 29/31 (93%), and 24/26
(92%) positive samples confirmed by xenodiagnosis,
and that were reactive by EIA, IIF, or IHA, respectively.
Discussion
The main strategies to prevent transfusion-associated
Chagas’ disease include the identification of putative
infectious blood donors by risk history and by
serological screening tests [1]. Since specific IgG levels
rise soon after infection and titers of these antibodies
remain high for life, the identification of T. cruzi-infected
blood donors by serological tests has become the most
accepted prophylactic alternative [14,15]. Typically,
the sensitivity and specificity rates of the serological
tests, which are available to detect antibodies to T.
cruzi, are very high when sera from patients with
infection confirmed by xenodiagnosis or from persons
who are not exposed to T. cruzi infection are tested.
However, there are many discrepancies among
techniques when they are carried out to identify putative
infectious blood donors [16].
We used 1951 sera obtained from Brazilian blood
donors, without risk history for T. cruzi infection, for
evaluating three serological assays routinely used for
the detection of IgG antibodies against T. cruzi. When
the results of three tests were submitted to a latent class
model, we found not only a high sensitivity rate (100%)
for the EIA and IIF techniques, but also a high
specificity rate of 99.95% and 99.69% for the EIA
and IIF, respectively. Although, the estimated sensitivity
rate for IHA was quite low (60.02%), this test showed
a high specificity rate (100%). The probability of being
case according to latent class model analysis was
99.92% when both EIA and IIF tests were positive,
and 100% for the association of the EIA, IIF, and IHA
techniques.
Based on the estimated 100% sensitivity of EIA
and IIF, if these tests are used in isolation there is still a
possibility for a false positive result, since their estimated
specificity is less than 100% (Table 3). However, based
on the latent class model results, in all instances where
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Table 1. Results of the serological tests and the RIPA technique for the 17 blood donors samples repeatedly
reactive for Trypanasoma cruzi antibodies
Table 2. Results of the RIPA in samples repeatedly reactive by serological tests performed to identify chronically
Trypanasoma cruzi-infected blood donors
Diagnosis of T. cruzi Infection in Blood Banking
EIA
Sample # sample/cut-off ratio IHA titer IIF titer RIPA
3397 1.5 Negative 1:20 p32+, p34+
7497 1.4 Negative Negative Not done
71406 3.2 Negative 1:20 Not done
71440 3.2 1:1280 1:160 p32+, p34+
2673 2.2 Negative 1:40 Not done
448 3.4 1:1280 1:80 p32+, p34+
75254 1.5 Negative 1:40 p32+, p34+
75315 3.6 1:80 1:160 p32+, p34+
76224 2.9 1:2560 1:160 p32+, p34+
76233 3.2 1:40 1:160 Not done
66611 3.6 1:80 1:160 p32+
47410 Negative Negative 1:40 Negative
48010 Negative Negative 1:20 p32+, p34+
75337 Negative Negative 1:40 Not done
73311 Negative Negative 1:20 Negative
74211 Negative Negative 1:20 Negative
76411 Negative Negative 1:40 Negative
EIA, enzyme immunoassay; IHA, indirect hemaglutination; IIF, indirect immunofluorescence; RIPA,
radioimmunoprecipitation assay.
Reactive RIPA
Serological test samples Positive (%) Undetermined (%) Negative (%) Not done
EIA 11 6/7 (85.7) 1/7 (14.2) 0 4
IHA 6 4/6 (66.7) 1/6 (16.6) 0 1
IIF 16 7/12 (58.3) 1/12 (8.3) 4/12 (33.3) 4
EIA, IHA and IIF 6 4/5 (80) 1/5 (20) 0 1
EIA and IIF 4 2/2 (100) 0 0 2
BJID 2002; 6 (August) 185
Table 3. Sensitivity and specificity rates for EIA, IHA and IIF tests performed to identify blood donors chronically
infected with Trypanasoma cruzi
Table 4. Probability of being a Trypanasoma cruzi-infected blood donor according to the results of the EIA,
IHA and IIF tests
Diagnosis of T. cruzi Infection in Blood Banking
Sensitivity
Estimated Prevalence = 0.0051 SE = 0.0016 95% CI
(0.002 - 0.008)
Test Estimated Sensitivity (%) SE 95% CI
EIA 100 0.000 100 – 100
IHA 60.02 0.155 29.6 - 90.4
IIF 100 0.000 100 – 100
Specificity
Estimated Prevalence = 0.0051 SE = 0.0016 95% CI
(0.002 - 0.008)
Test Estimated Specificity (%) SE 95% CI
EIA 99.95 0.000 99.8 – 100
IHA 100 0.000 100 – 100
IIF 99.69 0.001 99.4 – 100
EIA, second generation enzyme immunoassay; IHA, indirect hemaglutination; IIF, indirect
immunofluorescence.
Probability of
EIA-A IHA-B IIF-B Being Case (%)
0 0 0 0
1 0 0 0
0 1 0 0
1 1 0 85.71
0 0 1 0
1 0 1 99.92
0 1 1 50.00
1 1 1 100
0 = Negative; 1 = Positive; EIA, second generation enzyme immunoassay; IHA, indirect
hemaglutination; IIF, indirect immunofluorescence.
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one of the two tests (EIA or IIF) was positive and the
other one negative, it was always considered a false
positive result (negative predictive value, NPV) [Table
3]. In contrast, when both EIA and IIF are positive
there is 99.92% confidence that the result comes from
a true positive case (positive predictive value, PPV)
[Table 3]. This very high PPV can be further increased
to 100% if the IHA test is also positive (Table 3).
The RIPA has been used to screen sera for anti-T.
cruzi IgG antibodies and to classify a sample as
confirmed seroreactive, indeterminate, or nonreactive.
Recently, a combination of two confirmatory assays,
ELISA and RIPA, has been reported to result in a
sensitivity and specificity approaching 100% [9,10].
The results observed with RIPA in our study are more
or less in accordance with what was demonstrated by
the latent class model, suggesting that when both EIA
and IIF are positive, the confidence that the result
comes from a true positive case (PPV) is near 100%
(Table 4). However,  RIPA is a very time-consuming
technique, the number of samples that can be analyzed
at a time is quite limited, and a more suitable technique
is still needed to confirm positive results found with the
serological screening assays routinely used in blood
banks to detect antibodies to T. cruzi.
Some countries have required that two tests be
performed for blood bank screening of Chagas’ disease
because substantial uncertainty surrounds the sensitivity
and specificity of the serological tests for T. cruzi
infection in blood donors, and no good gold standard
exists for unequivocally identifying infected subjects.
We explored the latent class analysis modeling
technique to circumvent this problem. According to our
results in this study, using latent class analysis, the
strategy of using two different serological techniques
seems to optimize test results as one can considerably
increase the PPV of being case going from one to two
tests. In contrast, not much is gained by adding a third
test if the first two tests are EIA and IFF (Table 4). In
conclusion, in the absence of a universally accepted
gold standard to confirm positive test results for
detecting T. cruzi-infected blood donors, by using the
latent class model, the most appropriate strategy seems
to be the association of EIA and IIF.
Abbreviations
T. cruzi = Trypanossoma cruzi; TA-CD =
transfusion-associated Chagas’ disease; EIA = enzyme
immunoassay; IHA = indirect hemaglutination; IIF =
indirect immunofluorescence; OD = optical density; FNR
= false negative rate; FPR = false positive rate; NPV =
negative predictive value; PPV = positive predictive value.
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